Evidence map›Paper›PMID 14671135›Full record

ArticleJournal of virology2004

Tetracycline-inducible packaging cell line for production of flavivirus replicon particles.

Tracey J Harvey, Wen Jun Liu, Xiang Ju Wang, Richard Linedale, Michael Jacobs, Andrew Davidson, Thuy T T Le, Itaru Anraku, Andreas Suhrbier, Pei-Yong Shi and 1 more

Open access · greenAbstract readEvaluation Study
In one paragraph

Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 70 citations in OpenAlex.

  1. Article
  2. Review
  3. Viral Replicon Systems and Their Biosafety Aspects.Applied biosafety : journal of the American Biological Safety Association · 2023
    Review
  4. Review
  5. The Delivery of mRNA Vaccines for Therapeutics.Life (Basel, Switzerland) · 2022
    Review
  6. Article
  7. Formulation and Delivery Technologies for mRNA Vaccines.Current topics in microbiology and immunology · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Tracey J HarveySir Albert Sakzewski Virus Research Centre, Royal Children's Hospital, Brisbane, Queensland, Australia.
Wen Jun Liu
Xiang Ju Wang
Richard Linedale
Michael Jacobs
Andrew Davidson
Thuy T T Le
Itaru Anraku
Andreas Suhrbier
Pei-Yong Shi
Alexander A Khromykh
QIMR Berghofer Medical Research Institute · AUUniversity of Queensland · AURoyal Children's Hospital · AUNew York State Department of Health · USUniversity College London · GB

Funding

Development of Kunjin replicon-based Ebloa vaccineR21AI053579 · NIAID · UNIVERSITY OF QUEENSLAND · PI KHROMYKH, ALEXANDER A · 2003 to 2004
$432k
NIAID NIH HHS 1 R21 AI053579-01A1NIAID NIH HHS R21 AI053579Wellcome Trust
6 · The paper itself

Abstract

We have previously developed replicon vectors derived from the Australian flavivirus Kunjin that have a unique noncytopathic nature and have been shown to direct prolonged high-level expression of encoded heterologous genes in vitro and in vivo and to induce strong and long-lasting immune responses to encoded immunogens in mice. To facilitate further applications of these vectors in the form of virus-like particles (VLPs), we have now generated a stable BHK packaging cell line, tetKUNCprME, carrying a Kunjin structural gene cassette under the control of a tetracycline-inducible promoter. Withdrawal of tetracycline from the medium resulted in production of Kunjin structural proteins that were capable of packaging transfected and self-amplified Kunjin replicon RNA into the secreted VLPs at titers of up to 1.6 x 10(9) VLPs per ml. Furthermore, secreted KUN replicon VLPs from tetKUNCprME cells could be harvested continuously for as long as 10 days after RNA transfection, producing a total yield of more than 10(10) VLPs per 10(6) transfected cells. Passaging of VLPs on Vero cells or intracerebral injection into 2- to 4-day-old suckling mice illustrated the complete absence of any infectious Kunjin virus. tetKUNCprME cells were also capable of packaging replicon RNA from closely and distantly related flaviviruses, West Nile virus and dengue virus type 2, respectively. The utility of high-titer KUN replicon VLPs was demonstrated by showing increasing CD8(+)-T-cell responses to encoded foreign protein with increasing doses of KUN VLPs. A single dose of 2.5 x 10(7) VLPs carrying the human respiratory syncytial virus M2 gene induced 1,400 CD8 T cells per 10(6) splenocytes in an ex vivo gamma interferon enzyme-linked immunospot assay. The packaging cell line thus represents a significant advance in the development of the noncytopathic Kunjin virus replicon-based gene expression system and may be widely applicable to the basic studies of flavivirus RNA packaging and virus assembly as well as to the development of gene expression systems based on replicons from different flaviviruses.

Indexed as

RepliconAnimalsCell LineChlorocebus aethiopsCricetinaeDengue VirusFlavivirusMiceTetracyclineVero CellsVirionVirus AssemblyWest Nile virusTetracycline

Identifiers

PMID14671135
PMCPMC303381
OpenAlexW2167096803

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.